Indeed, MATT is able to inhibit tumor growth and was a candidate chemotherapeutic agent; however, a clinical study indicated that MATT was no better than placebo at prolonging survival in gastric cancer patients.11 Nonetheless, it has been reported that MATT is a promising maintenance treatment following chemotherapy.12 Based on the robust inhibitory effect of MATT on MMPs, it is hypothesized that if MATT is efficiently delivered to the TME, this inhibition will enable the maintenance of the TME physical barrier and the resultant suppression of cancer metastasis, as well as angiogenesis. The gene discussed is TMEM79; the disease is cancer.